

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C12N 15/12, 15/85, C07K 13/00 C12Q 1/68, C12N 1/21	<b>A1</b>	<b>(11) International Publication Number:</b> WO 92/20795 <b>(43) International Publication Date:</b> 26 November 1992 (26.11.92)
<b>(21) International Application Number:</b> PCT/US92/04073 <b>(22) International Filing Date:</b> 14 May 1992 (14.05.92)  <b>(30) Priority data:</b> 702,770 17 May 1991 (17.05.91) US  <b>(71) Applicants:</b> CETUS ONCOLOGY CORPORATION [US/US]; 1400 Fifty-Third Street, Emeryville, CA 94608 (US). THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; Chapel Hill, NC (US).  <b>(72) Inventors:</b> HASKILL, John, Stephen ; 106 Fox Run, Chapel Hill, NC 27516 (US). BALDWIN, Albert, S., Jr. ; 782 Hold Mill Road, Chapel Hill, NC 27514 (US). RALPH, Peter ; 119 Crest View Drive, Orinda, CA 94563 (US).		<b>(74) Agent:</b> MCGARRIGLE, Philip, L., Jr.; Cetus Oncology Corporation, 1400 Fifty-Third Street, Emeryville, CA 94608 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> INHIBITOR OF NF- $\kappa$ B TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF		
<b>(57) Abstract</b>  Compositions and methods of using the same are described that have applications for the identification of prophylactics or therapeutics for the treatment of diseases resulting from altered gene expression, including genes that encode cytokines or related molecules.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NI	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

## INHIBITOR OF NF- $\kappa$ B TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF

This invention is in the field of molecular biology/biochemistry. Described  
5 herein are compositions that have applications for the identification of prophylactics or  
therapeutics preferably for the treatment of viral diseases or diseases resulting from the  
undesirable production of cytokines or antibody. More specifically, an inhibitory  
material is shown that effects the transcriptional activity of genes that encode various  
10 proteins, including genes that encode cytokines or related molecules, viral proteins and  
immunoglobulin.

Cytokines are small molecular weight proteins that have a myriad of biological  
functions (for background information, see Balkwill, F. R., et al., 1989, Immun.  
Today, 10:299). For example, cytokines are known to be capable of stimulating their  
own synthesis, as well as the production of other cytokines from a variety of cell types.  
15 They are also associated with disease. A good example is the presence of the cytokines  
interleukin-1 (IL-1) and tumor necrosis factor (TNF). IL-1 has been demonstrated to  
have multiple biological activities with the two prominent being fever production and  
lymphocyte activation. Moreover, both cytokines, alone or in combination, cause a  
shock state in animals that hemodynamically and hematologically is characteristic of  
20 septic shock in man caused by bacterial infection. TNF, in addition, has recently been  
shown to be involved in initiating the expression of human immunodeficiency virus in  
human cells that carry latent virus. Folks et al., 1989, PNAS (USA), 86:2365. TNF  
and IL-1 also play a role in various autoimmune diseases, particularly arthritis. Duff, et  
al., 1987, International Conference on Tumor Necrosis Factor and Related Cytotoxins,  
25 175:10.

In addition to IL-1 and TNF, another cytokine, IL-6, has recently been shown  
to be involved in infection, particularly sepsis, as well as in affecting the growth of  
tumor cells. Hack, et al., 1989, Blood, 74:1704, and Miki et al., 1989, FEB, 250: 607.  
IL-6 is also termed hybridoma growth factor, interferon-beta-2, B-cell stimulatory  
30 factor 2, 26 kD protein, and hepatocyte stimulating factor.

Adherence to an appropriate substratum has been shown to be important in  
transcriptional expression of cytokine mediators of inflammation produced by  
macrophages or monocytes, and adherence to different matrices has recently been  
shown to result in preferential gene induction (Sporn, S.A., et al., 1990, J. of Immun.,  
35 144:4434-4441; Thorens, B., et al., 1987, Cell, 48:671). For example, within 30  
minutes of monocyte adherence to plastic, a complex set of regulatory events is initiated  
as defined by rapid changes of mRNA levels of several inflammatory mediators and

proto-oncogenes (Haskill, S., *et al.*, 1988, *J. of Immunol.*, 140:1690). IL-1 $\beta$ , TNF- $\alpha$  and *c-fos* are rapidly elevated, whereas CSF-1 steady state mRNA levels increase by 90 minutes. In contrast, expression of *c-fms* and lysozyme is rapidly down-regulated. These genes are modulated by adherence to different biologically relevant substrates  
5 (Eierman, D.F., 1989, *J. of Immunol.*, 142:1970-1970).

Although high steady state mRNA levels of important mediators of inflammation are rapidly induced by adherence, adherence by itself is insufficient to cause efficient translation and secretion of IL-1 $\beta$ , TNF- $\alpha$ , or CSF-1 (Haskill, S., *et al.*, *supra*). Activation by a second signal, such as bacterial endotoxin, is required for  
10 the secretion of all three gene products. Thus, it is clear that signals derived from the act of adherence are likely to play a significant role in the activation and differentiation of monocytes allowing them to respond to infection and to influence the local tissue environment (Sporn, S.A., *supra*).

Recently, a protein termed NF- $\kappa$ B has been shown to be a transcriptional  
15 activator (Sen, R. and Baltimore, D., 1986, *Cell*, 46:705-716). This factor has been shown to bind to DNA regulatory regions of certain cytokine genes (Leonardo, M. and Baltimore, D., 1989, *Cell*, 58:227-229). Various agents cause the induction of nuclear NF- $\kappa$ B DNA-binding activity (Sen and Baltimore, *supra*). It is thus thought that NF- $\kappa$ B is a transcriptional regulator of gene expression for various cytokine genes. It  
20 would therefore be desirable to identify molecules that inhibit the effects of NF- $\kappa$ B since these would be useful to regulate the effects of cytokines in the inflammatory response.

It has recently been shown that NF- $\kappa$ B is associated with a 36 kD protein termed I $\kappa$ B (Baeurle, P. and Baltimore, D., 1988, *Cell*, 53:211-217; Baeurle, P. and  
25 Baltimore, D., 1988, *Science*, 242:540-546). NF- $\kappa$ B consists of proteins having molecular weights of 50 and 65 kD. I $\kappa$ B binds to the 65 kD subunit (Baeurle, P. and Baltimore, D., 1989, *Genes and Development*, 3:1689-1698). Finally, recent experimental evidence shows that phosphorylation of I $\kappa$ B blocks its inhibitory effect on DNA binding activity of NF- $\kappa$ B. This is consistent with the observation that  
30 protein kinases activate NF- $\kappa$ B DNA binding activity *in vitro* (Ghosh, S. and Baltimore, D., 1990, *Nature*, 344:678-682).

Because of the importance of I $\kappa$ B in regulating gene expression, it will be appreciated that the purification, cloning, and expression of this molecule will make available assays for identification of regulators of NF- $\kappa$ B and I $\kappa$ B that will have significant medical applications.

5 One aspect of the invention described herein consists of a description of a protein that inhibits transcriptional activation by NF- $\kappa$ B that has an approximate molecular weight of 34-38 kD.

A second aspect of the invention is the description of a cDNA sequence that encodes a protein that inhibits transcriptional activation by NF- $\kappa$ B that has an  
10 approximate molecular weight of 34-36 kD.

A third aspect of the invention is a description of methods for cloning and expressing a 34 kD transcriptional activation inhibitor.

A fourth aspect of the invention is a method for identifying medicaments using I $\kappa$ B that are useful for controlling diseases resulting from undesirable gene expression.

15 A fifth aspect of the invention is a method for identifying medicaments that enhance immune responses by their ability to block the effects of I $\kappa$ B.

A sixth aspect of the invention is the identification of transcriptional activator inhibitors having properties similar to the instantly described I $\kappa$ B, and methods of using such inhibitors to identify medicaments that would be useful to treat diseases  
20 resulting from undesirable gene expression.

A seventh aspect of the invention is a description of diagnostic procedures for detecting diseases as a function of I $\kappa$ B expression.

These and other aspects of the invention will become more fully appreciated upon a complete consideration of the invention described below.

25 Figure 1 shows the cDNA sequence of MAD-3.

Figure 2 shows the cDNA sequence of I $\kappa$ B, and the deduced protein sequence based thereon. The 1.6 kb size of the clone is close to that predicted from the transcript size on Northern analysis. The consensus tyrosine phosphorylation site and the possible PI-3 kinase binding domain is underlined, the predicted PKC phosphorylation  
30 site is overlined and the three ATTA (SEQ ID NO: 1) motifs are underlined and typed in bold. The ankyrin repeat domain (Lux *et al.*, 1990, *Nature*, 144:36-42) is typed in bold.

Figure 3 shows a Kyte-Doolittle hydrophilicity/hydrophobicity plot. The five ankyrin repeats are overlined and each repeat is marked. The predicted PI-3 kinase binding domain and the putative PKC kinase target sequences are also overlined.

Figure 4A shows in vitro transcribed IkB mRNA translates a 36-38 kD protein with properties of IkB. 10% SDS polyacrylamide gel analyzing reticulocyte lysates programmed with in vitro transcribed IkB mRNA (lane 1, WT) or with IkB mRNA transcribed from an AccI digested plasmid (lane 2,  $\Delta$ ). Protein was labelled with  $^{35}\text{S}$ -methionine. The mobilities of prestained molecular weight markers are shown.

Figure 4B shows gel mobility shift analyzing programmed reticulocyte lysates and nuclear extracts of PMA and PHA treated Jurkat T-cells. For all lanes the Class I MHC enhancer probe was used. The following protein sources were used: nuclear extracts of stimulated Jurkat T-cells (lane 1), Jurkat extracts plus IkB programmed lysates (lane 2, WT), Jurkat extracts plus lysates translated with mRNA from the AccI-deleted construct (lane 3,  $\Delta$ ), Jurkat extracts plus mock translated reticulocyte lysates alone (lane 5, MT). The large arrow indicates the mobility of the NF- $\kappa$ B/DNA complex and the small arrow indicates the mobility of the KBF1/DNA complex.

Figure 4C shows gel mobility shift assay characterizing the nuclear extracts of the stimulated Jurkat T-cells. The following protein sources were used: extracts of stimulated Jurkat T-cells (lanes 1-5), plus either antiserum to the p50 DNA-binding subunit of NF- $\kappa$ B (lane 4, I indicates immune antiserum) or pre-immune (P) serum (lane 5). The DNA probes are as indicated above the figure: MUT (MHC double point mutant probe), Ig $\kappa$  (immunoglobulin kappa), and MHC (Class I MHC enhancer probe). The large arrow indicates the mobility of the NF- $\kappa$ B/DNA complex and the small arrow indicates the mobility of the KBF1/DNA complex.

Figure 5A shows specificity of inhibition of DNA-binding activity by the IkB protein. Gel mobility shift analyzing various DNA-binding activities. The adenovirus MLTF and Oct-1 (OCTA) probes (as indicated) were incubated with nuclear extracts of stimulated Jurkat T-cells (lanes 1-3) plus IkB programmed lysates (lane 2, WT), or plus mock translated lysates (lane 3, MT). The Class I MHC enhancer probe was incubated with a phosphocellulose fraction from HeLa cells (lane 1) containing the DNA-binding activity H2TF1 (Baldwin and Sharp, 1987, Mol. Cell. Biol., 7:305-



313), plus I $\kappa$ B programmed lysates (lane 2, WT) or plus mock translated lysates (lane 3, MT).

Figure 5B shows gel mobility shift analyzing NF- $\kappa$ B in nuclear extracts of monocytes. The Class I MHC enhancer probe was incubated with nuclear extracts of freshly isolated monocytes (lane 1). Lane 2 included the addition of mock translated lysates (MT) and lane 3 included the addition of I $\kappa$ B translated lysates (WT). The large arrow indicates the mobility of the NF- $\kappa$ B/DNA complex and the small arrow indicates the mobility of the KBF1/DNA complex.

Figure 6 shows deoxycholate releases NF- $\kappa$ B DNA-binding activity from the I $\kappa$ B inhibition. Gel mobility shift using the Class I MHC enhancer probe with the following binding conditions: DNA-affinity purified NF- $\kappa$ B (lanes 1-3), plus I $\kappa$ B programmed lysates (lanes 2 and 3). Following incubation of the purified NF- $\kappa$ B with the I $\kappa$ B programmed extract, DOC was added followed by NP40 (lane 3). The arrow indicates the mobility of the NF- $\kappa$ B/DNA complex.

Figure 7A shows kinetics of induction, substrate specificity, and tissue distribution of I $\kappa$ B mRNA expression. Monocytes isolated by non-adherent techniques were plated on Type IV collagen coated plates and RNA was extracted from adherent cells at the time points indicated and assayed by Northern transfer analysis employing the original I $\kappa$ B cDNA clone insert as probe (Sporn *et al.*, 1990). Times analyzed were freshly isolated monocytes (T<sub>0</sub>), 30 minutes (30') and 1, 2, 4, and 8 hours post-adhesion to Type IV collagen coated plates. Levels of RNA were normalized by comparing intensity of ethidium bromide-stained 18 and 28s RNA bands.

Figure 7B shows monocytes plated on plastic dishes either uncoated or pre-treated with Type IV collagen, fibronectin, fibronectin complexed with anti-fibronectin (Eierman *et al.*, 1989). RNA was extracted at 4 hours and analyzed by Northern blotting using the I $\kappa$ B probe. RNA from endometriosis-derived inflammatory peritoneal macrophages and freshly isolated neutrophils (PMN) were also analyzed.

Figure 7C shows RNA from monocytes and various cell lines were analyzed by semi-quantitative PCR techniques to determine constitutive and inducible levels of I $\kappa$ B mRNA. RNA samples included human umbilical vein endothelium (HUVE) with or

without 4 hours stimulation with LPS; HeLa (carcinoma), RAJI (B-cell), HSB (T-cell) or S68 (glioblastoma) cells. Serial dilutions of 4 hours adhered monocyte cDNA was used for quantitative purposes. For comparison, cDNA from fresh monocytes and 4 hours adhered monocytes were examined for expression of the NF- $\kappa$ B transcript.

5       The invention described herein draws on previously published work and pending patent applications. By way of example, such work consists of scientific papers, patents or pending patent applications. All of these publications and applications, cited previously or below are hereby incorporated by reference.

10       The present invention concerns the isolation, identification, cloning, and expression of a particular factor, hereinafter referred to as NF- $\kappa$ B transcriptional activator inhibitor factor, or I $\kappa$ B. The inhibitor has been characterized with respect to certain of its molecular and chemical properties. Each of these will be discussed separately below.

15       Before discussing the subject invention I $\kappa$ B inhibitor, it is important to be aware that the inhibitor described herein consists of proteinaceous material having a defined chemical structure. However, the precise structure of the inhibitor depends on a number of factors, particularly chemical modifications known to occur to proteins. For example, since all proteins contain ionizable amino and carboxyl groups it is, of course, apparent that the inhibitor may be obtained in acidic or basic salt form, or in  
20       neutral form. It is further apparent, that the primary amino acid sequence may be augmented by derivatization using sugar molecules (glycosylation) or by other chemical derivatizations involving covalent, or ionic attachment to the inhibitor with, for example, lipids, phosphate, acetyl groups and the like, often occurring through association with saccharides. These modifications may occur in vitro, or in vivo, the  
25       latter being performed by a host cell through post-translational processing systems. It will be understood that such modifications, regardless of how they occur, are intended to come within the definition of the I $\kappa$ B inhibitor so long as the activity of the protein, as defined below, is not destroyed. It is to be expected, of course, that such modifications may quantitatively or qualitatively increase or decrease the biological  
30       activity of the molecule, and such chemically modified molecules are also intended to come within the scope of the invention.

35       "Cells" or "recombinant host" or "host cells" are often used interchangeably as will be clear from the context. These terms include the immediate subject cell, and, of course, the progeny thereof. It is understood that not all progeny are exactly identical to the parental cell, due to chance mutations or differences in environment.

As used herein the term "transformed" in describing host cell cultures denotes a cell that has been genetically engineered to produce a heterologous protein that possesses the activity of the native protein. Examples of transformed cells are described in the examples of this application. Bacteria are preferred microorganisms for producing the protein. Synthetic protein may also be made by suitable transformed yeast and mammalian host cells.

"Operably linked" refers to juxtaposition such that the normal function of the components can be performed. Thus, a coding sequence "operably linked" to control sequences refers to a configuration wherein the coding sequence can be expressed under the control of these sequences.

"Control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences which are suitable for procaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly, other as yet poorly understood, sequences. Eucaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

"Expression system" refers to DNA sequences containing a desired coding sequence and control sequences in operable linkage, so that hosts transformed with these sequences are capable of producing the encoded proteins. In order to effect transformation, the expression system may be included on a vector; however, the relevant DNA may then also be integrated into the host chromosome.

As used herein, the term "pharmaceutically acceptable" refers to a carrier medium which does not interfere with the effectiveness of the biological activity of the active ingredients and which is not toxic to the hosts to which it is administered. The administration(s) may take place by any suitable technique, including subcutaneous and parenteral administration, preferably parenteral. Examples of parenteral administration include intravenous, intraarterial, intramuscular, and intraperitoneal, with intravenous being preferred.

Finally, it is important to note that while the activity of the inhibitor I $\kappa$ B has been discussed as applied to regulating the transcriptional activity of NF- $\kappa$ B on the expression of genes involved in the inflammatory response or viral infection, it will be appreciated that its scope of inhibitory activity is wider as indicated by the presence of NF- $\kappa$ B in numerous cell lines not involved in inflammation or viral infection. Thus, as to the expression of these genes, I $\kappa$ B can be expected to be useful to identify inhibitors or stimulators of their expression as well.

Establishing a cDNA library containing the cDNA sequence that encodes a truncated cytokine inhibitor, identification of the cDNA sequence, and subcloning and expressing the sequence makes use of numerous methods known to the skilled practitioner. A general description of the methods and materials used is presented here  
5 for the convenience of the reader. More specifically, construction of suitable vectors containing the desired cytokine coding sequence employs standard ligation and restriction methods wherein isolated vectors, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and religated in the form desired.

Site specific DNA cleavage is performed by treating with suitable restriction  
10 enzyme(s) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes. See, e.g., New England Biolabs, Product Catalog. In general, about 1 µg of plasmid or DNA sequence is cleaved by one unit of enzyme in about 20 µl of buffer solution. In the examples herein, typically, an excess of restriction enzyme  
15 is used to insure complete digestion of the DNA substrate. Incubation times of about one hour to two hours at about 37°C are workable, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol followed by chromatography using a Sephadex  
20 G-50 spin column. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in Methods in Enzymology, 1980, 65:499-560.

Restriction cleaved fragments may be blunt ended by treating with the large  
25 fragment of *E. coli* DNA polymerase I, that is, the Klenow fragment, in the presence of the four deoxynucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 minutes at 20 to 25°C in 50 mM Tris pH 7.6, 50 mM NaCl, 6 mM MgCl<sub>2</sub>, 6 mM DTT and 10 mM dNTPs. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Treatment under appropriate conditions  
30 with S1 nuclease results in hydrolysis of single-stranded portions.

Ligations are performed in 15-30 µl volumes under the following standard conditions and temperatures: 20 mM Tris-Cl pH 7.5, 10 mM MgCl<sub>2</sub>, 10 mM DTT, 33 µg/ml BSA, 10 mM-50 mM NaCl, and 1 mM ATP, 0.3-0.6 (Weiss) units T4 DNA  
35 ligase at 14°C for "sticky end" ligation, or for "blunt end" ligations 1 mM ATP was used, and 0.3-0.6 (Weiss) units T4 ligase. Intermolecular "sticky end" ligations are usually performed at 33-100 µg/ml total DNA concentration. In blunt end ligations, the total DNA concentration of the ends is about 1 µM.

In vector construction employing "vector fragments," the vector fragment is commonly treated with bacterial alkaline phosphatase (BAP) in order to remove the 5' phosphate and prevent religation of the vector. BAP digestions are conducted at pH 8 in approximately 150 mM Tris, in the presence of Na<sup>+</sup> and Mg<sup>+2</sup> using about 1 unit of BAP per µg of vector at 60°C for about 1 hour. Nucleic acid fragments are recovered by extracting the preparation with phenol/chloroform, followed by ethanol precipitation. Alternatively, religation can be prevented in vectors which have been double digested by additional restriction enzyme digestion of the unwanted fragments.

In the constructions set forth below, correct ligations are confirmed by first transforming the appropriate *E. coli* strain with the ligation mixture. Successful transformants are selected by resistance to ampicillin, tetracycline or other antibiotics, or using other markers depending on the mode of plasmid construction, as is understood in the art. Miniprep DNA can be prepared from the transformants by the method of D. Ish-Howowicz *et al.*, 1981, Nucleic Acids Res., 9:2989 and analyzed by restriction and/or sequenced by the dideoxy method of F. Sanger *et al.*, 1977, PNAS (USA), 74:5463 as further described by Messing *et al.*, 1981, Nucleic Acids Res., 9:309, or by the method of Maxam *et al.*, 1980, Methods in Enzymology, 65:499.

Host strains used in cloning in M13 consists of *E. coli* strains susceptible to phage infection, such as *E. coli* K12 strain DG98 are employed. The DG98 strain has been deposited with ATCC July 13, 1984 and has Accession No. 1965.

Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described by Cohen, S.N. *et al.*, 1972, PNAS (USA) 69:2110, and modifications as described by Hanahan, D., 1983, J. Mol. Biol., 166:557-580 are used for procaryotes or other cells which contain substantial cell wall barriers. Infection with *Agrobacterium tumefaciens* (Shaw *et al.*, 1983, Gene 23:315) is used for certain plant cells. Transformations into yeast are carried out according to the method of Van Solingen *et al.*, 1977, J. Bacterial 130:946 and Hsiao *et al.*, 1979, PNAS (USA) 76:3829.

Several transfection techniques are available for mammalian cells without such cell walls. The calcium phosphate precipitation method of Graham and van der Eb, 1978, Virology, 52:546 is one method. Transfection can be carried out using a modification (Wang *et al.*, 1985, Science 228:149) of the calcium phosphate co-precipitation technique. Another transfection technique involves the use of DEAE-dextran (Sompayrac, L.M. *et al.*, 1981, PNAS (USA), 78:7575-7578). Alternatively, Lipofection refers to a transfection method which uses a lipid matrix to transport

plasmid DNA into the host cell. The lipid matrix referred to as Lipofectin Reagent is available from BRL.

Synthetic oligonucleotides are prepared by the triester method of Matteucci *et al.*, 1981, *J. Am Chem. Soc.* 103:3185 or using commercially available automated  
5 oligonucleotide synthesizers. Kinasing of single strands prior to annealing or for labeling is achieved using an excess, e.g., approximately 10 units of polynucleotide kinase to 0.1 mmole substrate in the presence of 50 mM Tris, pH 7.6, 10 mM MgCl<sub>2</sub>, 5 mM dithiothreitol, 1-2 mM ATP, 1.7 pmoles <sup>32</sup>P-ATP (2.9 mCi/mmole), 0.1 mM spermidine, 0.1 mM EDTA.

10 A specific nucleic acid sequence may be cloned into a vector by using primers to amplify the sequence which contain restriction sites on their non-complementary ends according to the general methods as disclosed in U.S. Patent No. 4,683,195, issued July 28, 1987, U.S. Patent No. 4,683,202, issued July 28, 1987, and U.S. Patent No. 4,800,159, issued January 24, 1989 the latter of which is incorporated herein by  
15 reference in its entirety. A modification of this procedure involving the use of the heat stable *Thermus aquaticus* (Taq) DNA polymerase has been described and characterized in European Patent Publication No. 258,017, published March 2, 1988 incorporated herein by reference in its entirety. Also useful is the Thermal Cycler instrument (Perkin-Elmer-Cetus) which has been described in European Patent Publication No. 236,069,  
20 published September 9, 1987 also incorporated herein by reference in its entirety.

Generally, the nucleic acid sequence to be cloned is treated with one oligonucleotide primer for each strand and an extension product of each primer is synthesized which is complementary to each nucleic acid strand. An alternative to the use of plasmid DNAs encoding the lymphokines of interest as template for polymerase  
25 chain reaction (hereinafter referred to as PCR) is the use of RNA from any cell producing these lymphokines as template for PCR as described in U.S. Patent No. 4,800,159. If RNA is the available starting material, the extension product synthesized from one primer when separated from its complement can serve as template for synthesized of the extension product of the other primer. As previously mentioned,  
30 each primer contains a restriction site on its 5' end which is the same as or different from the restriction site on the other primer. After sufficient amplification has occurred the amplification products are treated with the appropriate restriction enzyme(s) to obtain cleaved products in a restriction digest. The desired fragment to be cloned is then isolated and ligated into the appropriate cloning vector.

35 For portions of vectors derived from IκB cDNA or genomic DNA which require sequence modifications, site-specific primer directed mutagenesis is used. This

technique is now standard in the art, and is conducted using a primer synthetic oligonucleotide complementary to a single stranded phage DNA to be mutagenized except for limited mismatching, representing the desired mutation. Briefly, the synthetic oligonucleotide is used as a primer to direct synthesis of a strand complementary to the phage, and the resulting double-stranded DNA is transformed into a phage-supporting host bacterium. Cultures of the transformed bacteria are plated in top agar, permitting plaque formation from single cells which harbor the phage.

Theoretically, 50% of the new plaques will contain the phage having, as a single strand, the mutated form; 50% will have the original sequence. The plaques are transferred to nitrocellulose filters and the "lifts" hybridized with kinased synthetic primer at a temperature which permits hybridization of an exact match, but at which the mismatches with the original strand are sufficient to prevent hybridization. Plaques which hybridize with the probe are then picked and cultured, and the DNA is recovered. Details of site specific mutation procedures are described below in specific examples.

In the constructions set forth below, correct ligations for plasmid construction are confirmed by first transforming *E. coli* strain MM294, or other suitable host, with the ligation mixture. Successful transformants are selected by ampicillin, tetracycline or other antibiotic resistance or using other markers, depending on the mode of plasmid construction, as is understood in the art. Further screening of transformants is possible using the technique of colony hybridization essentially as described in Maniatis, T. *et al.* (*supra*:312-328). Briefly, colonies are lifted onto nitrocellulose filters and sequentially placed on each of four Whatman filters each saturated with one of the following solutions: (1) in 10% SDS; (2) .5 M NaOH/1 M NaCl; (3) 1.5 M NaCl, 1.5 M Tris pH 8.0; (4) 2 x SSC for approximately 5 minutes each. After cell lysis and binding the DNA, filters were prehybridized for .5 to 1 hour at 42°C in hybridization buffer containing 30% formamide followed by hybridization for 1-2 hrs at 42°C. Filters were washed three times in 2 x SSC and 0.1% SDS until background was reduced.

Plasmids from the transformants are then prepared according to the method of Clewell *et al.*, 1969, PNAS (USA) 62:1159, optionally following chloramphenicol amplification (Clewell, 1972, J. Bacterial 110:667). The isolated DNA is analyzed by restriction and/or sequenced by the dideoxy method of Sanger *et al.*, 1977, PNAS (USA), 74:5463 as further described by Messing *et al.*, 1981, Nucleic Acids Res. 9:309, or by the method of Maxam *et al.*, 1980, Methods in Enzymology 65:499.

The expression of DNA that encodes I $\kappa$ B inhibitor can be carried out in a wide variety of cell types. Procaryotes most frequently are represented by various strains of *E. coli*. However, other microbial strains may also be used, such as bacilli, for example, *Bacillus subtilis*, various species of *Pseudomonas*, or other bacterial strains.

- 5 In such procaryotic systems, plasmid vectors which contain replication sites and control sequences derived from a species compatible with the host are used. For example, *E. coli* is typically transformed using derivatives of pBR322, a plasmid derived from an *E. coli* species by Bolivar *et al.*, 1977, Gene 2:95. pBR322 contains genes for ampicillin and tetracycline resistance, and thus provides additional markers which can
- 10 be either retained or destroyed in constructing the desired vector. Commonly used procaryotic control sequences, which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (*lac*) promoter systems (Chang *et al.*, 1977, Nature 198:1056), the
- 15 tryptophan (*trp*) promoter system (Goeddel *et al.*, 1980, Nucleic Acids Res. 8:4057) and the lambda derived P<sub>L</sub> promoter (Shimatake *et al.*, 1981, Nature 292:128), and N-gene ribosome binding site, which has been made useful as a portable control cassette, U.S. Patent No. 4,711,845, issued December 8, 1987 and incorporated herein by reference in its entirety, which comprises a first DNA sequence that is the P<sub>L</sub> promoter
- 20 operably linked to a second DNA sequence corresponding to the N<sub>RBS</sub> upstream of a third DNA sequence having at least one restriction site that permits cleavage within 6 bp 3' of the N<sub>RBS</sub> sequence. U.S. Patent No. 4,666,848 issued May 19, 1987 and incorporated herein by reference in its entirety discloses additional vectors with enhanced expression capabilities. Also useful is the phosphatase A (*phoA*) system
- 25 described by Chang *et al.*, in European Patent Publication No. 196,864, published October 8, 1986, incorporated herein by reference. However, any available promoter system compatible with procaryotes can be used.

- In addition to bacteria, eucaryotic microbes, such as yeast, may also be used as hosts. Laboratory strains of *Saccharomyces cerevisiae*, Baker's yeast, are most used,
- 30 although a number of other strains are commonly available. While vectors employing the 2 micron origin of replication are illustrated (Broach, 1983, Meth. Enz. 101:307; U.S. Patent No. 4,803,164 incorporated herein by reference in its entirety), other plasmid vectors suitable for yeast expression are known (see, for example, Stinchcomb *et al.*, 1979, Nature 282:39, Tschempe *et al.*, 1980, Gene 10:157 and Clarke *et al.*,
- 35 1983, Meth. Enz. 101:300). Control sequences for yeast vectors include promoters



for the synthesis of glycolytic enzymes (Hess *et al.*, 1968, *J. Adv. Enzyme. Res.* 7:149; Holland *et al.*, 1978, *Biochemistry* 17:4900).

Additional promoters useful in yeast host microorganisms and known in the art include the promoter for 3-phosphoglycerate kinase (Hitzeman *et al.*, 1980, *J. Biol. Chem.* 255: 2073), and those for other glycolytic enzymes, such as glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other promoters, which have the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization (Holland, *supra* ).

It is also believed that terminator sequences are desirable at the 3' end of the coding sequences. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. Many of the vectors illustrated contain control sequences derived from the enolase gene containing plasmid peno46 (Holland *et al.*, 1981, *J. Biol. Chem.* 256:1385) or the LEU2 gene obtained from YEp13 (Broach *et al.*, 1978, *Gene* 8:121); however, any vector containing a yeast compatible promoter, origin of replication and other control sequences is suitable.

It would be possible to express I $\kappa$ B in eucaryotic host cell cultures derived from multicellular organisms. See, for example, *Tissue Culture* Academic Press, Cruz and Patterson, editors (1973). Useful host cell lines include murine myelomas N51, VERO and HeLa cells, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and late promoters from Simian Virus 40 (SV 40) (Fiers *et al.*, 1978, *Nature*, 273:113) viral promoters such as those derived from polyoma, Adenovirus 2, bovine papilloma virus, or avian sarcoma viruses, or immunoglobulin promoters and heat shock promoters. A system for expressing DNA in mammalian systems using the BPV as a vector is disclosed in U.S. Patent No. 4,419,446, incorporated herein by reference in its entirety. A modification of this system is described in U.S. Patent No. 4,601,978, incorporated herein by reference in its entirety. General aspects of mammalian cell host system transformations have been described by Axel in U.S. Patent No. 4,399,216 issued August 16, 1983. Also useful is gene amplification in eucaryotic cells as described by Ringold in U.S. Patent No. 4,656,134, issued April 7, 1987, incorporated herein by reference in its entirety. It now appears also that "enhancer" regions are important in

optimizing expression; these are, generally, sequences found upstream of the promoter region. Origins of replication may be obtained, if needed, from viral sources. However, integration into the chromosome is a common mechanism for DNA replication in eukaryotes.

5 Plant cells are also now available as hosts, and control sequence compatible with plant cells such as the nopaline synthase promoter and polyadenylation signal sequences (Depicker *et al.*, 1982, *J. Mol. Appl. Gen.*, 1:561) are available. Additionally, methods and vectors for transformation of plant cells have been disclosed in PCT Publication No. WO 85/04899, published November 7, 1985, and incorporated  
10 herein by reference in its entirety.

Host strains typically used in cloning, expression and sequencing of recombinant constructs are as follows. For cloning, sequencing, and for expression of construction under control of most bacterial promoters, *E. coli* strain MM294 obtained from *E. coli* Genetic Stock Center GCSC #6135, may be used as the host. For  
15 expression under control of the P<sub>L</sub>N<sub>RBS</sub> promoter, *E. coli* strain K12 MC1000  $\lambda$  lysogen, N<sub>7</sub>N<sub>53</sub>CI857 SusP<sub>80</sub>, a strain deposited with the American Type Culture Collection (ATCC 39531), may be used. *E. coli* DG116, which was deposited with the ATCC (ATCC 53606) on April 7, 1987, may also be used.

For M13 phage recombinant, *E. coli* strains susceptible to phage infection,  
20 such as *E. coli* K12 strain DG98, are employed. The DG98 strain has been deposited with the ATCC (ATCC No. 39768) on July 13, 1984.

Mammalian expression has been accomplished in COS-A2 cells and also can be accomplished in COS-7, and CV-1, hamster and murine cells. Insect cell-based expression can be in *Spodoptera frugiperda*.

25 A full length cDNA sequence that encodes the I $\kappa$ B inhibitor may be obtained using molecular biology techniques well known in the art, with the noted exceptions detailed below.

Several procedures are available for identifying the relevant cDNA sequences. The preferred procedure is to generate a library using RNA isolated from adherent  
30 monocytes, but a library can be generated from virtually any source of biological material that expresses the inhibitor; indeed, cDNA libraries can even be purchased commercially. Monocytes are the preferred starting material because adherence to an appropriate surface induces the expression of the I $\kappa$ B inhibitor.

An illustrative procedure for making a cDNA library containing the inhibitor  
35 sequences consists of isolating total cytoplasmic RNA from a suitable starting material,

and further isolating messenger RNA therefrom. The latter can be further fractionated into Poly (A+) messenger RNA, which in turn may be fractionated further still into Poly (A+) messenger RNA fractions containing cytokine inhibitor messenger RNA. The messenger RNA can then be reverse transcribed and cloned into a suitable vector to form the cDNA library.

More specifically, the starting material (i.e., tissue, cells) is washed with phosphate buffered saline, and a non-ionic detergent, such as ethylene oxide, polymer type (NP40) is added in an amount to lyse the cellular, but not nuclear membranes, generally about 0.3%. Nuclei can then be removed by centrifugation at 1,000 x g for 10 minutes. The post-nuclear supernatant is added to an equal volume of TE (10 mM Tris, 1 mM ethylenediaminetetraacetic acid (EDTA), pH 7.5) saturated phenol/chloroform (1:1) containing 0.5% sodium dodecyl sulfate (SDS) and 10 mM EDTA. The supernatant is re-extracted 4 times and phase separated by centrifugation at 2,000 x g for 120 minutes. The RNA is precipitated by adjusting the samples to 0.25 M NaCl, adding 2 volumes of 100% ethanol and storing at -20°C. The RNA is then pelleted at 5,000 x g for 30 minutes, washed with 70% and 100% ethanol, and dried. This represents the total cytoplasmic RNA.

Alternatively, total cytoplasmic RNA may be isolated using the guanidine isothiocyanate-cesium chloride method as described by Chirgwin *et al.*, 1979, Biochemistry, 18:5294.

Polyadenylated (Poly A+) messenger RNA (mRNA) can be obtained from the total cytoplasmic RNA by chromatography on oligo (dT) cellulose (J. Aviv *et al.*, 1972, PNAS, 69:1408-1412). The RNA is dissolved in ETS (10 mM Tris, 1 mM EDTA, 0.5% SDS, pH 7.5) at a concentration of 2 mg/ml. This solution is heated to 65°C for 5 minutes, then quickly chilled to 4°C. After bringing the RNA solution to room temperature, it is adjusted to 0.4 M NaCl and slowly passed through an oligo (dT) cellulose column previously equilibrated with binding buffer (500 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 7.5). The flow-through is passed over the column twice more, and the column washed with 10 volumes of binding buffer. Poly (A+) mRNA is eluted with aliquots of ETS, extracted once with TE-saturated phenol chloroform and precipitated by the addition of NaCl to 0.2 M and 2 volumes of 100% ethanol. The RNA is reprecipitated twice, washed once in 70% and then 100% ethanol prior to drying. The poly (A+) mRNA can then be used to construct a cDNA library.

cDNA can be made from the enriched mRNA fraction using oligo (dT) priming of the poly A tails and AMV reverse transcriptase employing the method of H. Okayama *et al.*, 1983, Mol. Cell Biol. 3:280, incorporated herein by reference.

Other methods of preparing cDNA libraries are, of course, well known in the art. One, now classical, method uses oligo (dT) primer, reverse transcriptase, tailing of the double stranded cDNA with poly (dG) and annealing into a suitable vector, such as pBR322 or a derivative thereof, which has been cleaved at the desired restriction site and tailed with poly (dC). A detailed description of this alternate method is found, for example, in EP No. 109,748, published May 30, 1984, and assigned to the same assignee, incorporated herein by reference.

A preferred method by which a cDNA clone that encodes the I $\kappa$ B inhibitor may be identified is to employ a cDNA library that is produced using RNA obtained from induced monocytes, and to detect individual clones that differentially hybridize to cDNA probes produced using RNA from induced and uninduced monocytes. Clones that preferentially hybridize to cDNA probes produced from induced but not uninduced monocyte RNA will contain cDNA that encodes the cytokine inhibitor of the instant invention.

cDNA inserts may be sequenced using known techniques. The preferred technique is to subclone the inserts into an appropriate vector, an exemplary vector being pGEM blue (Promega Biotec. Madison, Wisconsin Corp.), and sequence the double stranded DNA using the dideoxy chain termination method described by Sanger et al., 1977, PNAS (USA), 74:5463. Sequencing is conveniently performed using commercially available kits, preferably the Sequenase sequencing kit produced by United States Biochemical Co. Cleveland, Ohio, and using suitable primers, such as T7 and SP6 obtainable from Promega Biotec. Madison, Wisconsin, and sequence specific primers.

To confirm that a cDNA sequence does encode I $\kappa$ B, gel mobility shift assays may be performed. The assay is based on the observation that NF- $\kappa$ B binds to a defined DNA in the absence but not the presence of I $\kappa$ B. The assay consists of detecting the effect of I $\kappa$ B, produced by reticulocyte translation, on the binding of NF- $\kappa$ B to a Class I MHC enhancer sequence, TGGGGATTCCCCA (SEQ ID NO: 2). Previously, this enhancer sequence has been demonstrated to bind to NF- $\kappa$ B (Baldwin, and Sharp, P., 1988 PNAS (USA), 85:723-727). The source of NF- $\kappa$ B in the assays may be nuclear extracts of a variety of cell types, but the preferred source is mitogen and phorbol ester induced Jurkat T-cells. The induction NF- $\kappa$ B in this cell line is well documented (Nabel, G. and Baltimore, D., 1987, Nature, 326:711-713).

The gel mobility shift assay is conducted by incubating appropriate amounts of the following materials: nuclear extracts obtained from Jurkat cells and/or rabbit reticulocyte lysates, either with I $\kappa$ B mRNA or without, and an appropriate labelled MHC enhancer binding probe. The reaction is conducted in a buffered solution containing appropriate amounts of the following: sodium chloride, EDTA, DTT, poly dI-dC (Pharmacia) and glycerol. The reaction is preferably conducted at room temperature for about 15 minutes and then subjected to electrophoresis on a non-denaturing 5% polyacrylamide gel using a Tris/glycine/EDTA buffer as described by Baldwin, A., 1990, DNA & Protein Eng. Tech., 2:73-76. The gel is dried and autoradiographed overnight using known techniques in the art.

Using the above described gel mobility shift assay, cDNA clones that encode I $\kappa$ B can be identified by their ability to eliminate or reduce the binding of NF- $\kappa$ B to the MHC enhancer DNA binding probe.

Further tests may be conducted to confirm that a cDNA sequence encodes I $\kappa$ B and not a molecule that non-specifically binds to a variety of DNA enhancer binding proteins. These tests may be conducted using the gel mobility shift assay essentially as described above, but with the substitution of a different DNA enhancer sequence and/or a different transcription regulator for NF- $\kappa$ B. A variety of such proteins were tested including KBF1, MLTF, Oct-1 or H2T1.

It will be appreciated by those skilled in the art, that knowledge of the DNA sequence that encodes I $\kappa$ B enables the synthesis of nucleotide probes that can be used to measure the expression of I $\kappa$ B in biological systems using techniques known in the art. This in turn will facilitate the identification of chemicals that induce or suppress the expression of I $\kappa$ B. The identification of such chemicals would have value as medicaments, while a determination of the levels of I $\kappa$ B expression would have diagnostic value.

Having described what the applicants believe their invention to be, the following examples are presented to illustrate the invention, and are not to be construed as limiting the scope of the invention.

Example 1Cloning of IκB

The preferred procedure for constructing a cDNA library that contains a cDNA sequence that encodes the IκB inhibitor is to generate the library from RNA isolated from adherent monocytes. These procedures are described by Sporn, S. A. et al., J. of Immunol., 1990, 144:4434. Briefly, the starting material consists of adherent monocytes. Monocytes may be obtained fresh from human volunteers, or from the American Red Cross. In both instances, the monocytes are isolated from whole blood initially in the form of a mononuclear cell fraction prepared by Ficoll-Hypaque sedimentation methods known in the art. Boyun, A., 1968, Scandinavian J. of Clinical Lab. Invest., 21:77. The monocytes are then isolated from the mononuclear fraction by density fractionation using Percoll. Ulmer, A.J., and Flad, D.H., 1979, J. of Immunological Methods, 30:1. Alternatively, monocytes may be isolated by plating them onto plastic tissue culture dishes as described by Eierman, D.F., et al., 1989, J. of Immunology, 142:1970.

The monocytes are induced to express of the IκB inhibitor by seeding the monocytes onto tissue culture plates or collagen coated tissue culture plates as generally described by Eierman, D.F., et al., 1989, J. Immunol., 142:1970. A variety of materials may be used to coat the tissue culture plates to effect monocyte adherence, and include fibronectin. Briefly, 100 mm tissue culture plates are coated with 100 μg/ml of human fibronectin in phosphate buffered saline (PBS) for 45 minutes at 37°C. Excess fibronectin is removed by washing the plates with PBS and the plates air dried before use. Monocytes are seeded onto the plates and are adherent to the tissue culture plates for at least the 30 minutes prior to the total RNA being extracted therefrom. The monocytes are cultured in RPMI 1640 media containing 20 μg/ml of gentamicin sulfate at 37°C in an atmosphere of 95% air/5%CO<sub>2</sub>. Generally, about 1-2 x 10<sup>7</sup> cells are seeded per 100 mm dish.

Next, adherent monocytes are lysed after removing the culture medium by adding 3.5 ml of a solution containing 4 M guanidinium thiocyanate solution previously prepared by mixing 50 g of Fluka pure grade material with 0.5 g of sodium N-lauroylsarcosine (final concentration 0.5%), 2.5 ml of 1 M sodium citrate, pH 7.0 (25 mM), and 0.7 ml of 2-mercaptoethanol (0.1 M). The solution is made up to 100 ml with deionized water, and filtered to remove any insoluble material. The pH was adjusted to 7 with 1 M NaOH.

Next, the monocyte RNA is separated from the guanidinium thiocyanate homogenate by ultra centrifugation through a dense cushion of cesium chloride. Technical grade cesium chloride is made 5.7 M and buffered with 0.1 M EDTA, pH 7, or 25 mM sodium acetate or citrate, pH 5. The solution is sterilized with 0.2% diethyl pyrocarbonate, and filtered through a 0.45  $\mu$ m Millipore filter. The monocyte RNA in the guanidinium thiocyanate is then separated from the guanidinium thiocyanate by ultracentrifugation through the cesium chloride cushion. The RNA pellets that form after the ultracentrifugation are redissolved if necessary by brief heating at 68°C in a water bath, or by first extracting excess cesium chloride from the RNA pellets with ethanol and drying with nitrogen. RNA isolated in this manner may be used to prepare an appropriate cDNA library.

Total RNA isolated as described above may be used for construction of a cDNA library using those methods described by Watson and Jackson, 1985, DNA Cloning, 1:79, "A Practical Approach", (D.M. Glover, ed.), IRL Press, Oxford; and Huynh, et al., 1985, "Constructing and Screening Libraries in Lambda GT10 and Lambda GT11", DNA Cloning, 1:49, A Practical Approach, (D.M. Glover, ed.), IRL Press, Oxford. This method entails converting the RNA to double stranded cDNA using AMV reverse transcriptase and the Klenow fragment DNA polymerase 1, as is known in the art. EcoRI linkers were ligated to the double stranded cDNA fragments, size selected and packaged into  $\lambda$  gt 10 vector using a commercially available packaging extract, Gigapack (Stratagene, San Diego, CA). This library contained about  $5.3 \times 10^6$  recombinants at a frequency of about  $7 \times 10^7$  per  $\mu$ g of DNA.

From the library described above, a sub-library was derived by selecting 4,000 clones that do not hybridize to a  $^{32}$ P-labelled first-strand cDNA probe that was made using RNA obtained from uninduced monocytes.

The sub-library described above was screened by differential hybridization with  $^{32}$ P-labelled first-strand cDNA probes prepared by reverse transcription of RNA isolated from monocytes that adhere for either 30 minutes or 4 hours, or from controlled non-adherent monocytes. Those plaques which exhibited hybridization with the cDNA probe made from adhered monocytes compared to non-adhered monocytes were selected, and rescreened with the probe. This resulted in the isolation of a 350 base pair fragment termed MAD-3, which represents a partial sequence of IkB. Note that the MAD-3 sequence is nearly identical to bases 783-1117 of the IkB cDNA with the exception that there is an additional triplet, TGA, in MAD-3. The sequence of MAD-3 is shown in Figure 1. A full length IkB clone was obtained using MAD 3 to probe a

second cDNA library made from mRNA isolated from adhered monocytes and neutrophils. The mRNA was reversed transcribed and the cDNA cloned into the pcDNA 1 vector. This vector is available from In Vitrogen Corporation. Screening of this library yielded several full-length clones, and one of these was sequenced.

### Example 2

#### DNA Sequence of IκB

cDNA inserts were subcloned into the double-stranded vector pGEM blue (Promega Biotec, Madison, WI). dscDNA sequencing was performed by the dideoxy chain termination method (as described in Sanger, F.S., *et al.*, 1977, PNAS (USA), 74:5463) by using the Sequenase sequencing kit (United States Biochemical Co., Cleveland, OH) with T7 and SP6 primers (Promega), as well as sequence-specific oligonucleotide primers. Figure 2 shows the cDNA sequence of IκB.

The sequence of IκB shows that it is about 1550 base pairs in length, and extends 94 base pairs 5' of a Kozak consensus sequence for the predicted start site of translation. The 3' untranslated region displays three ATTTA (SEQ ID NO: 3) motifs that are associated with rapid turnover of mRNA (Kaput D., *et al.*, 1986, PNAS (USA), 83:1670-1674). The poly A tail begins at the end of the base pair 1550.

The deduced amino acid sequence of IκB is shown in Figure 2, and is based on the cDNA sequence. The protein would have 317 amino acids, and thus have approximate molecular weight of 34 kD. The molecule is characterized in having three apparent domains. The first, the N-terminal domain, exhibits a 72 amino acid hydrophilic stretch that contains a consensus sequence, DEEYEQMVK (SEQ ID NO: 4), for tyrosine phosphorylation. The second domain, the C-terminal domain, contains a consensus sequence for PKC phosphorylation, RPSTR (SEQ ID NO: 5), and a region rich in PEST (SEQ ID NO: 6) residues, amino acids 264-314 which are associated with rapid protein turnover. The third domain consists of amino acids 74-242, which comprises five tandem repeats of the ankyrin consensus sequence (Lux S.E. *et al.*, 1990, Nature, 344:36-42). Figure 3 shows a Kyte-Doolittle hydrophilicity/hydrophobicity plot. The five ankyrin repeats are overlined and each repeat is marked. The predicted tyrosine phosphorylation domain and the putative PKC kinase target sequences are also overlined.



Example 3I $\kappa$ B Assays

The I $\kappa$ B DNA sequence in the expression plasmid, pcDNA 1, was used to generate RNA using SP6 RNA polymerase. The RNA was translated in a rabbit  
5 reticulocyte lysate mixture in the presence of <sup>35</sup>S-methionine, and the products analyzed on a 10% SDS polyacrylamide gel. As a control, mock translated lysates were run. Figure 4A shows the results. Since the reticulocyte lysate used for translation contained an endogenous NF- $\kappa$ B-like activity (data not shown), the lysates were depleted for this activity using a DNA affinity matrix specific for NF- $\kappa$ B. These NF-  
10  $\kappa$ B-depleted reticulocyte lysates demonstrated virtually no Class I MHC enhancer binding activity (see Figure 4B, lane 5). The reticulocyte lysates were then used to translate either full length I $\kappa$ B mRNA, or mRNA derived from an AccI digest of the cDNA or were mock translated. AccI cuts the I $\kappa$ B cDNA at the position corresponding to amino acid 167 in the third ankyrin repeat. The in vitro translated products, labelled  
15 with <sup>35</sup>S-methionine, were electrophoresed on a 10% SDS polyacrylamide gel. As predicted from the cDNA, the full length I $\kappa$ B mRNA and the mRNA from the AccI-digested plasmid revealed approximately 36 and 22 kD proteins (Figure 4A, lanes 1 and 2).

Briefly, the reticulocyte translation reaction was conducted as follows. 2  $\mu$ g of  
20 pcDNA1 containing full length I $\kappa$ B cDNA was digested with BamHI or with AccI. The restriction enzyme cuts downstream of the cDNA insert. The reaction digest was phenol/chloroform extracted, ethanol precipitated and used to synthesize RNA in a 100  $\mu$ l reaction for 1 hour at 37°C using SP6 RNA polymerase following the conditions recommended by the manufacturer (Boehringer Mannheim). The resulting RNA was  
25 extracted twice with phenol/chloroform, ethanol precipitated and redissolved in 20  $\mu$ l of water. Synthesis of RNA was confirmed by electrophoresis using agarose gels.

However, before conducting the translation reaction, rabbit reticulocyte lysates were first depleted of an endogenous NF- $\kappa$ B-like DNA-binding activity. This was performed by adding 10  $\mu$ l of lysate to 20  $\mu$ l of DNA affinity resin previously washed  
30 with deionized water. This procedure is described below. The binding reaction was performed, with frequent mixing, for 10 minutes at room temperature. The mixture was pelleted by brief centrifugation in a microfuge and the supernatant was removed for

in vitro translation reactions. Next, 4  $\mu$ l of RNA was used for in vitro translation in a rabbit reticulocyte lysate system obtained from Promega Biotech. The conditions for performing the reaction were those recommended by the manufacturer. The resulting  $^{35}$ S-methionine labelled products were analyzed on a 10% SDS polyacrylamide gel as described by Laemmli U., 1970, Nature, 227:680-685. The gel was dried and exposed for autoradiography using standard methods.

The DNA affinity resin contained the MHC Class I enhancer sequence TGGGGATTCCCCA (SEQ ID NO: 2), covalently linked to cyanogen bromide activated Sepharose 4B (Sigma). The resin was made and the purification of NF- $\kappa$ B carried out essentially by the method of Kadonaga and Tjian (1986). Nuclear extracts of PMA and PHA stimulated Jurkat T-cells were used for the NF- $\kappa$ B purification.

Jurkat nuclear extracts were incubated with the resin for 20 minutes and the NF- $\kappa$ B was eluted with a salt gradient. Only one round of DNA affinity chromatography was performed.

To determine that the I $\kappa$ B cDNA sequence does encode a molecule that binds to NF- $\kappa$ B, gel mobility shift assays were performed. The assay consisted of detecting the binding of I $\kappa$ B produced by reticulocyte translation to NF- $\kappa$ B on acrylamide gels as revealed by binding of a Class I MHC enhancer sequence, TGGGGATTCCCCA (SEQ ID NO: 2). Previously, this enhancer sequence has been demonstrated to bind to NF- $\kappa$ B (Baldwin, and Sharp, P., 1988 PNAS (USA), 85:723-727). The source of NF- $\kappa$ B in the assays was nuclear extracts of mitogen and phorbol ester induced Jurkat T-cells (described below). The induction of NF- $\kappa$ B in this cell line is well documented (Nabel, G. and Baltimore, D., 1987, Nature, 326:711-713), and, furthermore, there is an activity having the properties ascribable to KBF1.

The gel mobility shift assay was conducted as follows. 10  $\mu$ g of nuclear extracts obtained from Jurkat cells and/or 1  $\mu$ l of rabbit reticulocyte lysates, either with I $\kappa$ B mRNA or without, and 10,000 counts/minute of N-labelled MHC enhancer binding probe were incubated in 10 mM Tris, pH 7.7, 50 mM sodium chloride, 0.5 mM EDTA, 1 mM DTT, 2  $\mu$ g poly dI-dC (Pharmacia) and 10% glycerol in a final volume of 20  $\mu$ l. The reaction was conducted at room temperature for 15 minutes and then subjected to electrophoresis on a non-denaturing 5% polyacrylamide gel using a Tris/glycine/EDTA buffer as described by Baldwin, A., 1990, DNA & Protein Eng.

Tech., 2:73-76. Electrophoresis was conducted for approximately 2 hours at 20 mA. The gel was dried and autoradiographed overnight at -70°C using known techniques in the art.

The DNA/protein complexes indicated by the arrows in Figure 4 appear by various criteria to be NF- $\kappa$ B and KBF1. Addition of the I $\kappa$ B programmed lysates inhibited the DNA-binding activity associated with the slower NF- $\kappa$ B/DNA complex (indicated by the large arrow, Figure 4B, lane 2) in the stimulated Jurkat T nuclear extracts and only weakly affected the factor associated with the faster moving KBF1/DNA complex (indicated by the small arrow, Figure 4B, lane 2). Addition of either lysates programmed with the deleted mRNA or mock translated lysates did not affect either DNA-binding activity (Figure 4B, lanes 3 and 4).

To further characterize the DNA-binding activities in the nuclear extracts of the PMA and PHA stimulated Jurkat cells, several assays were performed. We first demonstrated that the two activities identified by the arrows are specific for the MHC enhancer probe as they do not interact with a double point mutated probe (Figure 4C, lane 1). We have previously shown that this mutant probe TGCGGATTCCCGA (SEQ ID NO: 7) is not bound by NF- $\kappa$ B (Baldwin and Sharp, 1988, above). The factors associated with the slower and faster complexes interact equally well with immunoglobulin kappa and Class I MHC enhancer probes (Figure 4C, lanes 2 and 3), consistent with these activities being NF- $\kappa$ B and KBF1. Finally, the two DNA/protein complexes are recognized by antibodies against the p50 subunit of NF- $\kappa$ B (Figure 4C, lane 4) but not by pre-immune serum (Figure 4C, lane 5). Thus, the I $\kappa$ B protein strongly inhibits an authentic NF- $\kappa$ B activity from stimulated Jurkat T-cells and may inhibit the Jurkat KBF1 activity very weakly.

Nuclear extracts were prepared from Jurkat T-cells using the method of Swick *et al.*, 1989, Nucleic Acids Res., 17:9291-9304. The cells were grown in RPMI 1640 medium containing 10% fetal calf serum. If desired, the cells were stimulated with phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (PMA). These were used at final concentrations of 1  $\mu$ g/ml and 50 ng/ml, respectively.

To demonstrate that the observed inhibition is specific for the NF- $\kappa$ B activity, we analyzed the affect of the I $\kappa$ B protein on other characterized DNA-binding proteins (Figure 5A). I $\kappa$ B did not inhibit the DNA-binding activity of the major late transcription factor (Carthew *et al.*, 1985, Cell, 43:439-448; also known as USF), the

Oct-1 factor (Singh, *et al.*, 1986, *Nature*, 319:154-158), or H2TF1, a Class I MHC enhancer binding factor (Baldwin and Sharp, 1987). We next analyzed whether NF- $\kappa$ B from another cell source would be inhibited by the translated I $\kappa$ B protein. NF- $\kappa$ B from nuclear extracts of freshly isolated monocytes was inhibited by the I $\kappa$ B protein, but the KBF1 activity found in these cells was unaffected (Figure 5B). Both the NF- $\kappa$ B and KBF1 activities in these extracts are recognized by antibodies to the p50 NF- $\kappa$ B subunit. Thus, the I $\kappa$ B protein is highly specific for NF- $\kappa$ B from several cell sources and has little or no effect on KBF1 DNA binding activity (Figures 4B and 5B). These results are consistent with the observation that I $\kappa$ B interacts with the 65 kD subunit of NF- $\kappa$ B, which is absent in KBF1 (Kieran *et al.*, 1990, *Cell*, 62:1007-1018). We, therefore, conclude that the I $\kappa$ B translation product specifically inhibits NF- $\kappa$ B DNA -binding activity and does not inhibit the DNA-binding activity of KBF1, MLTF, Oct-1 or H2TF1.

The DNA-binding probes are labelled HindIII-EcoRI digests of pUC plasmids containing oligonucleotides cloned into the polylinker with BamHI restriction ends. The sequence of the Class I MHC enhancer probe is GGCTGGGGATTCCCCATCT (SEQ ID NO: 8) and the mutant MHC probe is GGCTGCGGATTCCCGATCT (SEQ ID NO: 9) (Baldwin and Sharp, 1987), the sequence of the MLTF probe is ACCCGGTCACGTGGCCTACA (SEQ ID NO: 10), the sequence of the Oct-1 probe is ATGCAAAT (SEQ ID NO: 11), and the sequence of the immunoglobulin kappa probe is CAGAGGGACTTTCCGAGA (SEQ ID NO: 12).

Thus, based on the experiments presented above, it is concluded that the cDNA sequence that encodes I $\kappa$ B produces a protein that specifically inhibits NF- $\kappa$ B DNA binding activity, and does not inhibit the activities associated with KBF1, MLTF, Oct-1, or H2TF1.

Another characteristic of I $\kappa$ B is that it can be released from NF- $\kappa$ B with sodium deoxycholate (DOC). Once I $\kappa$ B is released from NF- $\kappa$ B, NF- $\kappa$ B can then bind to DNA. Thus, to further characterize I $\kappa$ B, we treated a reticulocyte lysate programmed with I $\kappa$ B mRNA with sodium deoxycholate, and NP40 and the treated mixture tested in a gel mobility shift assay as described previously. Endogenous NF- $\kappa$ B was

removed by DNA affinity chromatography, as described above, to remove endogenous NF- $\kappa$ B/I $\kappa$ B complexes. Similar to crude nuclear extracts of stimulated Jurkat T-cells, (Figure 4B), the I $\kappa$ B translation product inhibits this partially purified NF- $\kappa$ B (Figure 6, lane 2).

5           More specifically, 10  $\mu$ g of nuclear extracts containing NF- $\kappa$ B was reacted with 1  $\mu$ l of I $\kappa$ B programmed lysates or mock translated lysates under the binding conditions described above. The reactions were kept at room temperature for 10 minutes followed by the addition of 2  $\mu$ g of poly dI-dC and 10,000 cpm of radiolabelled DNA probe. The reactions were then loaded onto a 5% polyacrylamide  
10   Tris/glycine/EDTA gel and analyzed as described above. For the dissociation reactions, 0.8% sodium deoxycholate was added to the binding reactions (minus poly dI-dC and probe) followed by 1.2% NP40. Poly dI-dC and probe were added and incubated at room temperature for 15 minutes. These reactions were electrophoresed and analyzed as described above. Treatment of the NF- $\kappa$ B/I $\kappa$ B reaction with sodium deoxycholate  
15   (DOC) followed by NP40 incubation released NF- $\kappa$ B DNA-binding activity (Figure 6, lane 3). Thus, the release of NF- $\kappa$ B DNA-binding activity from the reaction is derived from NF- $\kappa$ B/I $\kappa$ B complexes and not from any endogenous NF- $\kappa$ B/I $\kappa$ B in the extract. Since NF- $\kappa$ B DNA-binding activity can be recovered from performed NF- $\kappa$ B/I $\kappa$ B by DOC treatment, we conclude that I $\kappa$ B encodes a protein with properties of I $\kappa$ B.

#### Example 4

##### Tissue Distribution of I $\kappa$ B

The presence of the I $\kappa$ B inhibitor of the instant invention in various tissues/cells was determined using Northern blot analysis or PCR.

25           Northern blot analysis consisted of isolating total RNA from the tissue to be tested using the guanidine isothiocyanate-cesium chloride method as described by Haskill *et al.*, above. Filters were hybridized at 43°C and washed to a final stringency of 0.2 x SSC at 56°C using I $\kappa$ B as a probe.

30           PCR analysis was conducted using 1  $\mu$ g of total RNA isolated as described above, whereby the RNA was converted into first strand DNA using random hexamers as described Kawasaki *et al.*, 1989, Detection of Gene Expression in, PCR

Technology (ed. Erlich), H.A. (Stockton, New York), pages 89-97. Next, amplification was carried out with a 5'-TCGTCCGCGCCATGTTCCAG (SEQ ID NO: 13) (base pair 85-103) and 3' anti-sense primer GCGGATCACTTCCATGGTCAG (SEQ ID NO: 14) (base pair 359-379). So that transcript frequencies could be compared from one tissue type to another, dose response curves were determined at the same PCR cycle number, 30, as test samples. Standards included I $\kappa$ B cDNA at various dilutions, as well as RNA isolated from monocytes that had adhered for 4 hours to a substratum that induces I $\kappa$ B expression. NF- $\kappa$ B primers were synthesized using the published sequences of Kieran *et al.*, 1990, *Cell*, 62:1007-1018. The sense primer was TAGAGCAACCTAAACAGAG (SEQ ID NO: 15) (base pair 316-335) and the anti-sense primer, TCATTCGTGCTTCCAGTGT (SEQ ID NO: 16) (base pair 629-648).

Figure 7A shows that I $\kappa$ B is not seen in freshly Percoll-isolated monocytes (T<sub>0</sub>), but is induced by binding to Type IV collagen.

Northern analysis revealed that I $\kappa$ B is highly expressed in monocytes adherent to different substrates and in blood neutrophils and is also present in endometriosis associated peritoneal inflammatory macrophages. These results are shown in Figure 7B.

PCR analysis revealed constitutive expression of I $\kappa$ B mRNA in a number of samples examined (Figure 7C). This included HSB and RAJI cells, glioblastoma cells, G82, and HUVE cells. The amount of I $\kappa$ B could be increased by activation of HUVE cells by LPS, causing approximately a 9-fold increase in I $\kappa$ B expression. Adherence of HUVE cells caused a 80-fold increase in expression. Expression of NF- $\kappa$ B is also shown for T<sub>0</sub> and 4 hour plastic-adherent monocytes. I $\kappa$ B was also observed to be present in several melanoma cell lines, and the level of expression is enhanced 2-3-fold by exposure to PMA, but little or no increase is observed after exposure to IL-2 or TNF (not shown).

#### Example 5

##### Identification of Medicaments

I $\kappa$ B may be used in a suitable assay format to identify medicaments that enhance or inhibit gene expression. Purified recombinant or naturally occurring I $\kappa$ B may be used in combination with NF- $\kappa$ B to identify chemicals that inhibit the formation

of I $\kappa$ B/NF- $\kappa$ B complex formation, or that stabilize the complex once formed.

Alternatively, *in vitro* transcription and translation of I $\kappa$ B can be employed, as discussed below. The materials and methods for carrying out these procedures are described above, and incorporated herein by reference.

- 5           Chemicals that inhibit or prevent complex formation would enhance gene expression by increasing the amount of free NF- $\kappa$ B to bind to an appropriate DNA sequence, while those that stabilize the complex would prevent or retard gene expression by regulating the amount of free NF- $\kappa$ B available.

- For example, to identify chemicals that inhibit complex formation, the I $\kappa$ B  
10   DNA sequence in the expression plasmid, pcDNA 1, would be used to generate RNA using SP6 RNA polymerase. The RNA may be translated in a rabbit reticulocyte lysate mixture in the presence of <sup>35</sup>S-methionine, and an aliquot combined with NF- $\kappa$ B in the presence or absence of chemicals being tested for inhibitory activity. A source of NF- $\kappa$ B would be stimulated Jurkat T-cells, prepared as described above. The reaction  
15   products could then be analyzed in a gel mobility shift assay. Chemicals that inhibit complex formation would produce little or no shift in the gel assay compared to the control.

- To identify chemicals that stabilize the I $\kappa$ B/NF- $\kappa$ B complex, chemicals can be tested for their capacity to maintain the complex in the presence of deoxycholate. The  
20   assays for dissociating the I $\kappa$ B/NF- $\kappa$ B complex in deoxycholate/NP40 are described in Example 3, and the instant assay would be conducted similarly but with the addition of the chemical being tested followed by a gel shift assay. Chemicals that stabilize the complex would prevent I $\kappa$ B dissociation from NF- $\kappa$ B and this would be detected by reduced binding of NF- $\kappa$ B to the radiolabelled MHC Class I enhancer probe.

- 25           Although any similar or equivalent methods and materials may be employed in the practice or testing of the present invention, the preferred methods and materials are now described. The following examples are illustrative of this invention. They are not intended to be limiting upon the scope thereof.

- 30           The present invention has been described with reference to specific embodiments. However, this application is intended to cover those changes and substitutions which may be made by those skilled in the art without departing from the spirit and the scope of the appended claims.

Deposit of Biological Materials: The following plasmid which encodes IκB have been deposited with the American Type Culture Collection.

5	<u>Designation</u>	<u>ATCC No.</u>	<u>Date of Deposit</u>
	pC3.A in the <i>E. coli</i> host DH5		5-16-91



## WE CLAIM:

1. An isolated nucleotide sequence which encodes a protein that binds to NF- $\kappa$ B that reduces or eliminates NF- $\kappa$ B binding to DNA.
2. An isolated nucleotide sequence as described in claim 1, wherein said sequence comprises DNA or RNA.
3. An isolated nucleotide sequence as described in claim 2, wherein said  
10 sequence encodes I $\kappa$ B.
4. A cDNA sequence that encodes I $\kappa$ B.
5. A cDNA sequence as described in claim 4, wherein said sequence  
15 comprises the sequence shown in Figure 2.
6. Cells transformed with the cDNA sequence of claim 5.
7. Vectors comprising the cDNA sequence of claim 5.
8. A protein encoded by the cDNA sequence of claim 5.
9. Recombinant I $\kappa$ B.
- 25 10. A complex comprising recombinant I $\kappa$ B and NF- $\kappa$ B.
11. A cDNA sequence that encodes a protein comprising I $\kappa$ B activity, said cDNA sequence comprising three domains wherein said first domain encodes the N-terminal of said protein having a hydrophilic stretch of about 72 amino acids and  
30 containing a consensus sequence, DEEYEQMVK (SEQ ID NO: 4); a second domain encoding five tandem repeats of a consensus sequence present in ankyrin; and a third domain encoding the C-terminal sequence of said protein comprising a first, RPSTR (SEQ ID NO: 5), and a second, PEST (SEQ ID NO: 6), consensus sequence.

12. A method of identifying a chemical that is a medicament that increases gene expression, comprising the steps of:

- 5           a)     contacting a complex comprising I $\kappa$ B and NF- $\kappa$ B with said chemical;  
              and  
              b)     identifying said chemical as a medicament by its capacity to dissociate  
                      said complex.

13. A method of identifying a chemical that is a medicament that decreases gene expression comprising the steps of:

- 10           a)     combining in solution I $\kappa$ B, NF- $\kappa$ B, and said chemical, said I $\kappa$ B and  
                      NF- $\kappa$ B being present in amounts sufficient to form a complex  
                      comprising I $\kappa$ B and NF- $\kappa$ B; and identifying said chemicals as a  
                      medicament by its capacity to prevent or retard the dissociation of I $\kappa$ B  
                      from said complex.

14. A method of treating an animal suffering from a disease resulting from gene under expression, comprising administering to said animal an effective amount of said medicament of claim 12.

- 20           15. A method of treating an animal suffering from a disease resulting from  
                      gene over expression, comprising administering to said animal an effective amount of  
                      said medicament of claim 13.

16. Medicaments identified by the method of claim 12.

17. Medicaments identified by the method of claim 13.

18. A method of diagnosing a person suspected of having a disease  
                      resulting from gene over expression, comprising determining if the expression of I $\kappa$ B  
30   in said person is reduced relative to a person not suspected of having said disease.

19. A method as described in claim 18, wherein said expression of I $\kappa$ B is  
determined by measuring the amount of I $\kappa$ B, or I $\kappa$ B mRNA.

20. A method of diagnosing a person suspected of having a disease resulting from gene under expression, comprising determining if the expression of I $\kappa$ B in said person is increased relative to a person not suspected of having said disease.

21. A method as described in claim 20, wherein said expression of I $\kappa$ B is determined by measuring the amount of I $\kappa$ B or I $\kappa$ B mRNA.

1/7

```

1  ctgacctggT  GTCACCTCCTG  TTGAAGTGTG  GGGCTGATGT  CAACAGAGTT
51  ACCTACCAGG  GCTATTCTCC  CTACCAGCTC  ACCTGGGGCC  GCCCAAGCAC
101  CCGGATACAG  CAGCAGCTGG  GCCAGCTGAC  ACTAGAAAAC  CTTTCAGATGC
151  TGCCAGAGAG  TGAGGATGAG  GAGAGCTATG  ACACAGAGTC  AGAGTTCACG
201  GAGTTCACAG  AGGACGAGCT  GCCCTATGAT  GATGACTGTG  TGTITGGAGG
251  CCAGCGTCTG  ACGTTATGAG  CAAAGGGGCT  GAAAGAACAT  GGACTTGCAT
301  ATTTGTACAA  AAAAAAAGT  TTTATTTTTC  TAAAAAATAA  AAAAAAATAA

```

FIG. 1




FIG. 3

**FIG. 2A**

3/7


P H L H S I L K A T N Y N G H T C L H L  
 AGCCTCTATCCATGGCTACCTGGGCAATCGTGGAGCTTTTGGTGTCTTGGTGGTGTGATGT  
 189  
 720  
 A S I H G Y L G I V E L L V S L G A D V  
 CAATGCTCAGGAGCCCTGTAATGGCCGACTGCCCTTCACTCGCAGTGGACCTGCAGAAA  
 209  
 780  
 N A Q E P C N G R T A L H L A V D L Q N  
 TCCTGACCTGGTGTCACTCCTGTGAAGTGTGGGCTGATGTCAACAGAGTTACCTACCA  
 229  
 840  
 P D L V S L L L K C G A D V N R V T Y Q  
 249  
 GGGCTATTCTCCCTACCAGCTCACCTGGGGCCGCCAAGCACCCGGATACAGCAGCAGCT  
 G Y S P Y Q L T W G R P S T R I Q Q Q L  
 900  
 269  
 GGGCAGCTGACACTAGAAAACCTTCAGATGCTGCCAGAGAGTGAAGATGAGGAGAGCTA  
 G Q L T L E N L Q M L P E S E D E S Y  
 960  
 289  
 TGACACAGAGTCAGAGTTCACGGAGTTCACAGAGGACGAGTGCCTATGATGACTGTGT  
 D T E S E F T E F T E D E L P Y D D C V  
 1020  
 309  
 GTTTGGAGGCCAGCGTCTGACGTTATGAGTGCAAGGGGCTGAAAGAACATGGACTTGT  
 F G G Q R L T L  
 1080  
 TATTGTACAAAAAAGTTTATTCTTCTAAAAAAGAAAAAAGAAAAAATTAA  
 317  
 1140  
 AGGGTGTAATATATCCACACTGCACACTGCCCTAGCCCAAAACGTCTTATTGTGGTAGGA  
 1200  
 TCAGCCCTCATTTTGTGCTTTTGTGAACCTTTTGTAGGGGACGAGAAAGATCATTGAAA  
 1260  
 TTCTGAGAAAACTTCTTTTAAACCTCACCTTTGTGGGTTTGTGGAGAGGTTATCAAAA  
 1320  
 ATTTGATGGAAGGACCAATTTTATTTATTTGCTTCGAGTGAAGTCAAGTCAAGTGT  
 1380  
 TCCTGTGACATGTACAGCCAGGAGTGTAAAGCGTTCAAGTGTGGGTGAAAGTTAC  
 1440  
 TACCTGTCAAGGTTTGTGTACCCCTCCTGTAATGGTGTACATAATGTATTGTGGTAAT  
 1500  
 TATTTGGTACTTTTATGATGTATATTTAATAAGAGATTTTACAAATG  
 1550

FIG. 2B

SUBSTITUTE SHEET

4/7

FIG. 4A




PROBE: MHC

EXTRACT: JURKAT +

RETIC: - WT Δ MT MT



FIG. 4B



SUBSTITUTE SHEET

EXTRACT: AFF. NF- $\kappa$ B  
 PROBE: MHC  
 RETIC: - WT WT  
 DOC: - - +

5/7



FIG. 6



1 2 3

EXTRACT: JURKAT +  
 Ab: I P MHC  
 PROBE: MHC  
 Ig $\kappa$   
 MUT




FIG. 4C



1 2 3 4 5



6 / 7




FIG. 5A




FIG. 5B

7/7




FIG. 7A




FIG. 7B





FIG. 7C

SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/04073

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5	C12N15/12; C12N1/21	C12N15/85; C07K13/00; C12Q1/68
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	C12N ; C07K ; C12Q	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	WO,A,8 908 147 (WHITEHEAD INSTITUTE FOR BIOCHEMICAL RESEARCH) 8 September 1989 * see the whole document especially the claims *	10, 12-17
P,X	CELL. vol. 65, 28 June 1991, CAMBRIDGE, MA US pages 1281 - 1289; S. HASKILL ET AL: 'Characterization of an immediate early gene induced in adherent monocytes that encodes IκB-like activity' see the whole document	1-17
X	NATURE. vol. 344, 12 April 1990, LONDON GB pages 678 - 682; S. GHOSH ET AL: 'Activation in vitro of NF-κB by phosphorylation of its inhibitor IκB' cited in the application see the whole document	1-4, 6-12, 14, 16
<p><sup>10</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
11 SEPTEMBER 1992	18. 09. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	LE CORNEC N.D.R. 	

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	CELL. vol. 61, April 1990, CAMBRIDGE, NA US pages 255 - 265; U. ZABEL ET AL: 'Purified human I $\kappa$ B can rapidly dissociate the complex of the NF- $\kappa$ B transcription factor with its cognate DNA' cited in the application see the whole document ---	1-12,14, 16
X	CELL. vol. 53, 22 April 1988, CAMBRIDGE, NA US pages 211 - 217; P. A. BAEUERLE ET AL: 'Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF- $\kappa$ B transcription factor' cited in the application see the whole document ---	10,12-17

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 14 and 15 are directed to a method of treatment of the animal body the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

US 9204073  
SA 60775

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 11/09/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8908147	08-09-89	EP-A- 0407411	16-01-91

**ПРОФОРМ Р0479**

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82